Vistagen Therapeutics Discloses New Corporate Presentation (Reg FD)

What Happened
Vistagen Therapeutics, Inc. announced on September 25, 2026 that it has begun using a new corporate presentation. The presentation is attached to the Current Report on Form 8‑K as Exhibit 99.1 and the disclosure was made under Regulation FD. The filing is signed by President and CEO Shawn K. Singh.

Key Details

• Date of disclosure: September 25, 2026.
• Exhibit attached: Exhibit 99.1 — Vistagen Therapeutics, Inc. Corporate Presentation (dated September 2026).
• Filing type: Form 8‑K, Item 7.01 (Regulation FD Disclosure); Exhibit listed under Item 9.01.
• The filing does not report earnings, revenue, executive changes, mergers/acquisitions, or other financial results.

Why It Matters
An updated corporate presentation can change how the company presents its strategy, pipeline progress, or investor priorities, so investors may want to review the attached slides for any new messaging. Because the disclosure was made under Regulation FD, Vistagen has publicly shared the material presentation to ensure fair disclosure. This 8‑K itself contains no financial results or management changes — it is an informational update about investor communications.